Document Detail

Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury.
MedLine Citation:
PMID:  8957224     Owner:  NLM     Status:  MEDLINE    
This study examined the effect of carvedilol, a vasodilating beta-adrenoceptor antagonist and antioxidant, on lethal reperfusion injury in feline hearts subjected to 40 min of regional ischemia and 180 min of reperfusion. 30 open chest anaesthetized cats were randomized into three groups. A control (n = 10) was compared with a group given carvedilol before coronary artery occlusions (n = 10) and a group given carvedilol immediately before and during early reperfusion (n = 10). Regional myocardial function was measured by sonomicrometry. Infarct size was determined by staining the left ventricle with triphenyl tetrazolium chloride. Myocardial blood flow was measured by radiolabeled microspheres. Tissue levels of glutathione were measured after reperfusion. Infarct size was significantly reduced compared to control both when carvedilol was given before ischemia (0.2 +/- 0.1 vs. 17.6 +/- 3.6%, P < 0.05). and when given immediately before reperfusion (3.7 +/- 1.3 vs. 17.6 +/- 3.6%, P < 0.05). Regional shortening improved significantly and the incidence of ventricular fibrillation during early reperfusion was reduced in both groups treated with carvedilol compared to control. Oxidized glutathione did not differ between groups in the post-ischaemic myocardium. This study supports that lethal reperfusion injury is a significant phenomenon. Furthermore, carvedilol reduces infarct size and reperfusion arrhythmias, and improves post-ischaemic regional myocardial function by protecting against both ischaemic and lethal reperfusion injury. The present study does not answer whether it is the non-selective beta- or alpha 1-receptor antagonism, the antiarrhythmic or the antioxidant actions of carvedilol that is responsible for the protective effect.
H Brunvand; L Frłyland; E Hexeberg; S E Rynning; R K Berge; K Grong
Related Documents :
11093494 - Cardioprotective effects of fk409, a nitric oxide donor, after isolated rat heart prese...
18446394 - P846, a new gadolinium based low diffusion magnetic resonance contrast agent, in charac...
10924084 - Glucocorticoid pretreatment protects cardiac function and induces cardiac heat shock pr...
7649214 - Control of myocardial reperfusion injury with hypertonic-hyperosmotic solution in isola...
16386664 - Comparison of b-type natriuretic peptides for assessment of cardiac function and progno...
17868954 - Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of ac...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of pharmacology     Volume:  314     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  1996 Oct 
Date Detail:
Created Date:  1997-03-10     Completed Date:  1997-03-10     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  99-107     Citation Subset:  IM    
Department of Surgery, University of Bergen, Haukeland Hospital, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacology*
Carbazoles / pharmacology*
Coronary Vessels / drug effects
Hemodynamics / drug effects
Myocardial Infarction / therapy*
Myocardial Reperfusion Injury / prevention & control*
Propanolamines / pharmacology*
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/Propanolamines; 0K47UL67F2/carvedilol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pulmonary versus systemic effects of vasodilator drugs: an in vitro study in isolated intrapulmonary...
Next Document:  The role of the 5-HT4 receptor in Cl- secretion in human jejunal mucosa.